geometrybase
8a0dfd88f0
Request: - Add extracted PDF text generation to the archivist workflow as a standard step. Changes: - Run PDF text extraction automatically for newly archived HKEX PDF sources. - Make the PDF text extractor incremental and manifest-preserving. - Document extracted-text handling in the archivist skill and README. - Mark generated extracted text as no-diff data evidence. - Backfill extracted text for all archived PDF source references. Verification: - Ran git diff --cached --check. - Ran .venv/bin/python -m py_compile scripts/extract_pdf_text.py scripts/archive_hkex_documents.py. - Ran full PDF extraction, then confirmed an incremental rerun skips unchanged files. - Verified 557 PDF source_refs, 557 manifest rows, all status ok, and zero missing text/hash/path issues. Next useful context: - HKEX HTML notices and Yahoo JSON market data remain under data/raw and are not expected in data/extracted_text.
1512 lines
41 KiB
Plaintext
1512 lines
41 KiB
Plaintext
--- page 1 ---
|
||
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange ”)
|
||
and Hong Kong Securities Clearing Company Limited ( “HKSCC ”) take no responsibility for the contents of this
|
||
announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability
|
||
whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this
|
||
announcement.
|
||
This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States
|
||
(including its territories and possessions, any state of the United States and the District of Columbia). This
|
||
announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for the Offer
|
||
Shares in the United States or in any other jurisdictions. The Offer Shares have not been, and will not be, registered
|
||
under the United States Securities Act of 1933 as amended from time to time (the “U.S. Securities Act ”) or securities
|
||
law of any state or other jurisdiction of the United States. The Offer Shares may not be offered, sold, pledged or
|
||
otherwise transferred within the United States, except pursuant to an exemption from the registration requirements of
|
||
the U.S. Securities Act and U.S. Investment Company Act of 1940, as amended ( “U.S. Investment Company Act ”),
|
||
and in compliance with any applicable state securities laws. The Offer Shares are being offered and sold outside the
|
||
United States to investors that are not U.S. persons nor persons acquiring for the account or benefit of U.S. persons in
|
||
reliance on Regulation S under the U.S. Securities Act. There will be no public offer of the Offer Shares in the United
|
||
States.
|
||
This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase
|
||
or subscribe for securities. This announcement is not a prospectus. Potential investors should read the prospectus dated
|
||
July 31, 2025 (the “Prospectus ”) issued by Ab&B Bio-Tech CO., LTD. JS ʮ̡
|
||
(the “Company ”) for detailed information about the Global Offering described below before deciding whether or not
|
||
to invest in the H Shares thereby being offered. Any investment decision in relation to the Offer Shares should be
|
||
taken solely in reliance on the information in the Prospectus.
|
||
Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those
|
||
defined in the Prospectus.
|
||
No stabilizing manager will be appointed, and it is anticipated that no stabilization activities will be carried out in
|
||
relation to the Global Offering.
|
||
Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of
|
||
the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting
|
||
Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting
|
||
– Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination ” in the
|
||
Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on
|
||
Monday, August 11, 2025).
|
||
|
||
|
||
--- page 2 ---
|
||
Ab&B Bio-Tech CO., LTD. JS
|
||
ʮ̡
|
||
(A joint stock company established in the People ’s Republic of China with limited liability)
|
||
GLOBAL OFFERING
|
||
Number of Offer Shares under the
|
||
Global Offering
|
||
: 33,442,600 H Shares
|
||
Number of Hong Kong Offer Shares : 3,996,000 H Shares (as adjusted after
|
||
reallocation)
|
||
Number of International Offer Shares : 29,446,600 H Shares (as adjusted
|
||
after reallocation)
|
||
Offer Price : HK$12.90 per H Share, plus brokerage
|
||
of 1.0%, SFC transaction levy of
|
||
0.0027%, Stock Exchange trading fee
|
||
of 0.00565% and AFRC transaction
|
||
levy of 0.00015%
|
||
Nominal value : RMB1.00 per H Share
|
||
Stock code : 2627
|
||
Joint Sponsors, Overall Coordinators,
|
||
Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers
|
||
Joint Bookrunners and Joint Lead Managers
|
||
|
||
|
||
--- page 3 ---
|
||
1
|
||
|
||
|
||
AB&B BIO-TECH CO., LTD. JS/江蘇中慧元通生物科技股份有限公司
|
||
ANNOUNCEMENT OF FINAL OFFER PRICE AND
|
||
ALLOTMENT RESULTS
|
||
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as
|
||
those defined in the prospectus dated July 31, 2025 (the “Prospectus”) issued by Ab&B Bio-Tech CO., LTD. JS
|
||
(江蘇中慧元通生物科技股份有限公司) (the “Company”).
|
||
|
||
Warning: In view of high concentration of shareholding in a small number of Shareholders,
|
||
Shareholders and prospective investors should be aware that the price of the H Shares could move
|
||
substantially even with a small number of H Shares traded and should exercise extreme caution when
|
||
dealing in the H Shares.
|
||
SUMMARY
|
||
Company Information
|
||
Stock Code 2627
|
||
Stock short name AB&B BIO-TECH-B
|
||
Dealings commencement date August 11, 2025*
|
||
*see note at the end of the announcement
|
||
Price Information
|
||
Final Offer Price HK$12.90
|
||
Maximum Offer Price HK$15.50
|
||
Offer Price Adjustment N/A
|
||
|
||
Offer Shares and Share Capital
|
||
Number of Offer Shares 33,442,600
|
||
Number of Offer Shares in Hong Kong Public Offering (after
|
||
reallocation)
|
||
3,996,000
|
||
Number of Offer Shares in International Offering (after the
|
||
Reallocation)
|
||
29,446,600
|
||
Number of issued Shares upon Listing 393,442,600
|
||
|
||
|
||
Offer Size Adjustment Option (Upsize option)
|
||
Number of additional shares issued under the option 0
|
||
- Public Offer 0
|
||
- International Offer 0
|
||
Note: The Offer Size Adjustment Option has not been exercised.
|
||
|
||
Proceeds
|
||
Gross proceeds (Note) HK$431.4 million
|
||
Less: Estimated listing expenses payable based on Final
|
||
Offer Price
|
||
HK$(48.7) million
|
||
Net proceeds HK$382.7 million
|
||
|
||
|
||
--- page 4 ---
|
||
2
|
||
|
||
|
||
Note: Gross proceeds refers to the amount which the Company is entitled to receive. For details of the use of
|
||
proceeds, please refer to the section headed “Future Plans and Use of Proceeds” of the Prospectus.
|
||
ALLOTMENT RESULTS DETAILS
|
||
HONG KONG PUBLIC OFFERING
|
||
|
||
No. of valid applications 191,879
|
||
No. of successful applications 18,948
|
||
Subscription level 4,007.64 times
|
||
Claw-back triggered No
|
||
No. of Offer Shares initially available under the Hong Kong Public
|
||
Offering
|
||
3,344,400
|
||
No. of Offer Shares reallocated from the International Offering 651,600
|
||
Final no. of Offer Shares under the Hong Kong Public Offering (after
|
||
reallocation)
|
||
3,996,000
|
||
% of Offer Shares under the Hong Kong Public Offering to the Global
|
||
Offering
|
||
11.95%
|
||
|
||
Note: For details of the final allocation of H Shares to the Hong Kong Public Offering, investors can refer to
|
||
www.hkeipo.hk/IPOResult to perform a search by identification document number or www.hkeipo.hk/IPOResult
|
||
for the full list of allottees.
|
||
INTERNATIONAL OFFERING
|
||
|
||
No. of placees 152
|
||
Subscription Level 0.99 times
|
||
No. of Offer Shares initially available under the International Offering 30,098,200
|
||
Final no. of Offer Shares under the International Offering (after
|
||
reallocation)
|
||
29,446,600
|
||
% of Offer Shares under the International Offering to the Global
|
||
Offering
|
||
88.05%
|
||
|
||
The Directors confirm that, to the best of their knowledge, information and belief , (i) none of the Offer Shares
|
||
subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the
|
||
Directors, Supervisors, chief executive of the Company, Controlling Shareholders, substantial Shareholders,
|
||
existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none
|
||
of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from
|
||
the C ompany, any of the Directors, Super visors, chief executive of the Company, Controlling Shareholders,
|
||
substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective
|
||
close associates in relation to the acquisition, disposal, voting or other disposition of H Shares registered in
|
||
his/her/its name or otherwise held by him/her/it.
|
||
The placees in the International Offering include the following:
|
||
|
||
|
||
--- page 5 ---
|
||
3
|
||
|
||
|
||
Cornerstone Investor
|
||
Investor Note 1
|
||
No. of Offer
|
||
Shares
|
||
allocated
|
||
% of Offer
|
||
Shares
|
||
% of total issued
|
||
H Shares after
|
||
the Global
|
||
Offering
|
||
% of total issued
|
||
share capital in
|
||
the Company
|
||
after the Global
|
||
Offering
|
||
Existing
|
||
shareholders or
|
||
their close
|
||
associates
|
||
Jiaxing Xinyang
|
||
Private Equity Asset
|
||
Management Co.,
|
||
Ltd. (嘉興鑫揚私募
|
||
基金管理有限公司
|
||
) ("Jiaxing
|
||
Xinyang") and
|
||
Huatai Capital
|
||
Investment Limited
|
||
("HTCI") (in
|
||
connection with
|
||
Huatai Back-to-back
|
||
TRS and Huatai
|
||
Client TRS)
|
||
7,830,600 23.42% 2.64% 1.99% No
|
||
Subtotal 7,830,600 23.42% 2.64% 1.99%
|
||
Note:
|
||
1. For further details of the Cornerstone Investor, please refer to the section headed “Cornerstone
|
||
Investor” in the Prospectus.
|
||
|
||
LOCK-UP UNDERTAKINGS
|
||
Controlling Shareholders
|
||
Name Note 1,2,3,4
|
||
Number of Shares held
|
||
in the Company
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
% of H Shares
|
||
subject to lock-up
|
||
undertakings as to
|
||
total issued H
|
||
Shares upon
|
||
Listing
|
||
% of Shares
|
||
subject to lock-up
|
||
undertakings as to
|
||
total issued Shares
|
||
upon Listing
|
||
Last day subject to the
|
||
lock-up undertakings
|
||
Jiangsu Tiaoyu
|
||
Science and Trade
|
||
Co., Ltd. (江蘇糶宇
|
||
科貿有限公司)
|
||
("Jiangsu Tiaoyu")
|
||
112,743,611
|
||
(including
|
||
78,920,528 H Shares)
|
||
26.63% 28.66%
|
||
February 10, 2026
|
||
(First Six-Month
|
||
Period) Note 5
|
||
|
||
August 10, 2026
|
||
(Second Six- Month
|
||
Period) Note 6
|
||
|
||
He Yiming (何一鳴
|
||
) ("Mr. He")
|
||
16,267,253
|
||
(including
|
||
11,387,077 H Shares)
|
||
3.84% 4.13%
|
||
February 10, 2026
|
||
(First Six-Month
|
||
Period) Note 5
|
||
|
||
|
||
--- page 6 ---
|
||
4
|
||
|
||
|
||
|
||
August 10, 2026
|
||
(Second Six- Month
|
||
Period) Note 6
|
||
Taizhou Huida
|
||
Enterprise
|
||
Management
|
||
Consulting Service
|
||
Partnership (Limited
|
||
Partnership) (泰州
|
||
慧達企業管理諮詢
|
||
服務合夥企業(有限
|
||
合夥)) ("Taizhou
|
||
Huida")
|
||
|
||
18,707,341
|
||
(including
|
||
18,642,272 H Shares)
|
||
6.29% 4.75%
|
||
February 10, 2026
|
||
(First Six-Month
|
||
Period) Note 5
|
||
|
||
August 10, 2026
|
||
(Second Six- Month
|
||
Period) Note 6
|
||
|
||
Taizhou Huirong
|
||
Enterprise
|
||
Management
|
||
Consulting Service
|
||
Partnership (Limited
|
||
Partnership)
|
||
(泰州慧融企業管理
|
||
諮詢服務合夥企業(
|
||
有限合夥))
|
||
("Taizhou
|
||
Huirong")
|
||
8,133,626
|
||
(including 8,133,626
|
||
H Shares)
|
||
2.74% 2.07%
|
||
February 10, 2026
|
||
(First Six-Month
|
||
Period) Note 5
|
||
|
||
August 10, 2026
|
||
(Second Six- Month
|
||
Period) Note 6
|
||
|
||
Taizhou Huilong
|
||
Enterprise
|
||
Management
|
||
Consulting Service
|
||
Partnership (Limited
|
||
Partnership)
|
||
(泰州慧隆企業管理
|
||
諮詢服務合夥企業(
|
||
有限合夥))
|
||
("Taizhou
|
||
Huilong")
|
||
8,133,626
|
||
(including 8,133,626
|
||
H Shares)
|
||
2.74% 2.07%
|
||
February 10, 2026
|
||
(First Six-Month
|
||
Period) Note 5
|
||
|
||
August 10, 2026
|
||
(Second Six- Month
|
||
Period) Note 6
|
||
|
||
Subtotal
|
||
163,985,457
|
||
(including
|
||
125,217,129 H
|
||
Shares)
|
||
42.25% 41.68%
|
||
|
||
Notes:
|
||
1. Jiangsu Tiaoyu is owned as to 70% by Mr. An Youcai (安有才) ("Mr. An") and 30% by Ms. Cao
|
||
Hong (曹紅), Mr. An’s spouse. Therefore, under the SFO, Mr. An is deemed to be interested in the
|
||
Shares held by Jiangsu Tiaoyu.
|
||
2. Jiangsu Tiaoyu is the general partner of each of Taizhou Huida, Taizhou Huirong, Taizhou Huilong,
|
||
Taizhou Huixin Enterprise Management Consulting Service Partnership (Limited Partnership) ( 泰
|
||
州慧新企業管理諮詢服務合夥企業(有限合夥)) ("Taizhou Huixin"), Taizhou Huining Enterprise
|
||
|
||
|
||
--- page 7 ---
|
||
5
|
||
|
||
|
||
Management Consulting Service Partnership (Limited Partnership) ( 泰州慧寧企業管理諮詢服務
|
||
合夥企業(有限合夥)) ("Taizhou Huining") and Taizhou Huijia Enterprise Management Consulting
|
||
Service Partnership (Limited Partnership) ( 泰州慧嘉企業管理諮詢服務合夥企業 (有限合夥 ))
|
||
("Taizhou Huijia ", together with Taizhou Huida, Taizhou Huirong, Taizhou Huilong, Taizhou
|
||
Huixin, Taizhou Huining, the " Employee Ownership Platforms"). Therefore, under the SFO, each
|
||
of Mr. An and Jiangsu Tiaoyu is deemed to be interested in Shares held by Taizhou Huida, Taizhou
|
||
Huirong, Taizhou Huilong, Taizhou Huixin, Taizhou Huining and Taizhou Huijia. For details of the
|
||
Employee Ownership Platforms, please refer to the section headed “History, Development and
|
||
Corporate Structure—Employee Ownership Platforms” of the Prospectus.
|
||
3. Pursuant to the concert party agreement entered into by Mr. An, Jiangsu Tiaoyu and Mr. He in
|
||
December 2022 (the "Concert Party Agreement"), Mr. He confirmed and agreed that he has acted
|
||
and will continue to act in concert with Mr. An, Jiangsu Tiaoyu and the Directors nominated by each
|
||
of them at the general meetings and Board meetings (as the case may be) in respect of the
|
||
management and operations of the Company for a period from January 1, 2020 until 36 months after
|
||
the signing date of the Concert Party A greement (being December 12, 2022) or, in the event when
|
||
the Shares of the Company are publicly offered and listed, 36 months after such offering and listing
|
||
of the Company on the Stock Exchange. Therefore, under the SFO, each of Mr. An, Jiangsu Tiaoyu
|
||
and Mr. He is deemed to be interested in the Shares held by each other.
|
||
4. Taizhou Huixin is the limited partner of Taizhou Huida, holding approximately 58.26% partnership
|
||
interests therein. Therefore, under the SFO, Taizhou Huixin is deemed to be interested in Shares held
|
||
by Taizhou Huida.
|
||
5. In accordance with the relevant Listing Rules/guidance materials, the required lock -up for the first
|
||
six-month period ends on February 10, 2026. The Controlling Shareholder may dispose of or transfer
|
||
Shares after the indicated date provided that the Controlling Shareholder will not cease to be a
|
||
Controlling Shareholder, subject to compliance with applicable requirements under the PRC
|
||
Company Law.
|
||
6. In accordance with the relevant Listing Rules/guidance materials, the required lock-up for the second
|
||
six-month period ends on August 10, 2026. The Controlling Shareholder will cease to be prohibited
|
||
from disposing of or transferring Shares after the indicated date, subject to compliance with
|
||
applicable requirements under the PRC Company Law.
|
||
|
||
Pre-IPO Investors
|
||
Name
|
||
Number of Shares
|
||
held in the
|
||
Company subject
|
||
to lock-up
|
||
undertakings upon
|
||
Listing
|
||
% of H Shares
|
||
subject to lock-up
|
||
undertakings as to
|
||
total issued H Shares
|
||
upon Listing
|
||
% of Shares subject to
|
||
lock-up undertakings as
|
||
to total issued Shares
|
||
upon Listing
|
||
Last day subject to
|
||
the lock-up
|
||
undertakings
|
||
Jiangsu Jiequan
|
||
Gaotejia Medical
|
||
Industry Investment
|
||
Fund (Limited
|
||
Partnership)
|
||
(江蘇疌泉高特佳醫
|
||
療產業投資基金(有
|
||
29,708,884
|
||
(including
|
||
14,854,442 H
|
||
Shares)
|
||
5.01% 7.55% August 10, 2026
|
||
Note 2
|
||
|
||
|
||
--- page 8 ---
|
||
6
|
||
|
||
|
||
Name
|
||
Number of Shares
|
||
held in the
|
||
Company subject
|
||
to lock-up
|
||
undertakings upon
|
||
Listing
|
||
% of H Shares
|
||
subject to lock-up
|
||
undertakings as to
|
||
total issued H Shares
|
||
upon Listing
|
||
% of Shares subject to
|
||
lock-up undertakings as
|
||
to total issued Shares
|
||
upon Listing
|
||
Last day subject to
|
||
the lock-up
|
||
undertakings
|
||
限合夥))
|
||
Zhuzhou National
|
||
Innovation Medicine
|
||
Investment Partnership
|
||
(Limited Partnership)
|
||
(株洲市國創新藥投
|
||
資合夥企業(有限合
|
||
夥)) ("Zhuzhou
|
||
National
|
||
Innovation") Note 3
|
||
9,645,017
|
||
(including
|
||
2,893,505 H
|
||
Shares)
|
||
0.98% 2.45% August 10, 2026
|
||
Note 2
|
||
Pingtan Wenzhou
|
||
Hangshi Ruihui
|
||
Investment Partnership
|
||
(Limited Partnership)
|
||
(平潭文周杭實瑞慧
|
||
投資合夥企業(有限
|
||
合夥)) ("Pingtan
|
||
Wenzhou Hangshi")
|
||
Note 3
|
||
8,593,339
|
||
(including
|
||
6,445,004 H
|
||
Shares)
|
||
2.17% 2.18% August 10, 2026
|
||
Note 2
|
||
Pingtan Wenzhou
|
||
Ruixi Investment
|
||
Partnership (Limited
|
||
Partnership)
|
||
(平潭文周瑞璽投資
|
||
合夥企業(有限合夥))
|
||
("Pingtan Wenzhou
|
||
Ruixi") Note 3
|
||
1,719,449
|
||
(including
|
||
1,289,587 H
|
||
Shares)
|
||
0.44% 0.44% August 10, 2026
|
||
Note 2
|
||
Zhuzhou Wenzhou
|
||
Junzhe Venture
|
||
Capital Partnership
|
||
(Limited Partnership)
|
||
(株洲市文周君喆創
|
||
業投資合夥企業(有
|
||
限合夥)) ("Zhuzhou
|
||
Wenzhou Junzhe")
|
||
Note 3
|
||
1,712,942
|
||
(including
|
||
1,284,706 H
|
||
Shares)
|
||
0.43% 0.44% August 10, 2026
|
||
Note 2
|
||
Qingdao Yingke Value
|
||
Venture Capital
|
||
Partnership (Limited
|
||
Partnership)
|
||
(青島盈科價值創業
|
||
投資合夥企業(有限
|
||
12,890,009
|
||
(including
|
||
6,445,004 H
|
||
Shares)
|
||
2.17% 3.28% August 10, 2026
|
||
Note 2
|
||
|
||
|
||
--- page 9 ---
|
||
7
|
||
|
||
|
||
Name
|
||
Number of Shares
|
||
held in the
|
||
Company subject
|
||
to lock-up
|
||
undertakings upon
|
||
Listing
|
||
% of H Shares
|
||
subject to lock-up
|
||
undertakings as to
|
||
total issued H Shares
|
||
upon Listing
|
||
% of Shares subject to
|
||
lock-up undertakings as
|
||
to total issued Shares
|
||
upon Listing
|
||
Last day subject to
|
||
the lock-up
|
||
undertakings
|
||
合夥)) ("Qingdao
|
||
Yingke Value
|
||
Venture") Note 4
|
||
Qingdao Yingke
|
||
Dingxin No. 1 Venture
|
||
Capital Partnership
|
||
(Limited Partnership)
|
||
(青島盈科鼎新一號
|
||
創業投資合夥企業(
|
||
有限合夥))
|
||
("Qingdao Yingke
|
||
Dingxin No. 1") Note 4
|
||
1,744,500
|
||
(including
|
||
872,250 H
|
||
Shares)
|
||
0.29% 0.44% August 10, 2026
|
||
Note 2
|
||
Pingtan Puxin Yingke
|
||
Ruiyuan Venture
|
||
Capital Partnership
|
||
(Limited Partnership)
|
||
(平潭浦信盈科睿遠
|
||
創業投資合夥企業(
|
||
有限合夥)) ("Pingtan
|
||
Puxin Yingke") Note 4
|
||
1,718,635
|
||
(including
|
||
1,718,635 H
|
||
Shares)
|
||
0.58% 0.44% August 10, 2026
|
||
Note 2
|
||
Zibo Yingke Growth
|
||
No. 2 Venture Capital
|
||
Partnership (Limited
|
||
Partnership)
|
||
(淄博盈科成長二號
|
||
創業投資合夥企業(
|
||
有限合夥))("Zibo
|
||
Yingke Growth No.
|
||
2") Note 4
|
||
833,534
|
||
(including
|
||
416,767 H
|
||
Shares)
|
||
0.14% 0.21% August 10, 2026
|
||
Note 2
|
||
Zhuzhou Sealand
|
||
Guochuang Qianjin
|
||
Pharmaceutical
|
||
Venture Capital
|
||
Partnership (Limited
|
||
Partnership)
|
||
(株洲市國海國創千
|
||
金醫藥創業投資合夥
|
||
企業(有限合夥))
|
||
("Zhuzhou Sealand
|
||
Guochuang") Note 5
|
||
6,015,305
|
||
(including 0 H
|
||
Shares)
|
||
0.00% 1.53% August 10, 2026
|
||
Note 2
|
||
Shenzhen Sealand No.
|
||
5 Innovative
|
||
Pharmaceutical
|
||
4,232,251
|
||
(including 0 H
|
||
Shares)
|
||
0.00% 1.08% August 10, 2026
|
||
Note 2
|
||
|
||
|
||
--- page 10 ---
|
||
8
|
||
|
||
|
||
Name
|
||
Number of Shares
|
||
held in the
|
||
Company subject
|
||
to lock-up
|
||
undertakings upon
|
||
Listing
|
||
% of H Shares
|
||
subject to lock-up
|
||
undertakings as to
|
||
total issued H Shares
|
||
upon Listing
|
||
% of Shares subject to
|
||
lock-up undertakings as
|
||
to total issued Shares
|
||
upon Listing
|
||
Last day subject to
|
||
the lock-up
|
||
undertakings
|
||
Investment Partnership
|
||
(Limited Partnership)
|
||
(深圳市國海伍號創
|
||
新醫藥投資合夥企業
|
||
(有限合夥))
|
||
("Shenzhen Sealand
|
||
No.5") Note 5
|
||
Guangxi Sealand
|
||
Yuchai Venture
|
||
Capital Partnership
|
||
(Limited Partnership)
|
||
(廣西國海玉柴金投
|
||
創業投資合夥企業(
|
||
有限合夥)) ("Sealand
|
||
Yuchai") Note 5
|
||
3,591,159
|
||
(including
|
||
3,591,159 H
|
||
Shares)
|
||
1.21% 0.91% August 10, 2026
|
||
Note 2
|
||
Xi’an Sealand
|
||
Jingheng Venture
|
||
Capital Co., Ltd.
|
||
(西安國海景恒創業
|
||
投資有限公司)
|
||
("Sealand Jingheng")
|
||
Note 5
|
||
2,052,114
|
||
(including
|
||
2,052,114 H
|
||
Shares)
|
||
0.69% 0.52% August 10, 2026
|
||
Note 2
|
||
HLC Healthmedical
|
||
HK Limited
|
||
12,030,772
|
||
(including
|
||
12,030,772 H
|
||
Shares)
|
||
4.06% 3.06% August 10, 2026
|
||
Note 2
|
||
Taizhou Jintai Hongyi
|
||
Entrepreneurship
|
||
Investment Fund
|
||
(Limited Partnership)
|
||
(泰州市金泰弘毅創
|
||
業投資基金(有限合
|
||
夥))
|
||
9,903,016
|
||
(including
|
||
9,903,016 H
|
||
Shares)
|
||
3.34% 2.52% August 10, 2026
|
||
Note 2
|
||
Hangzhou Sanhua
|
||
Hongdao Venture
|
||
Capital Partnership
|
||
Enterprise (Limited
|
||
Partnership)
|
||
(杭州三花弘道創業
|
||
投資合夥企業(有限
|
||
合夥)) ("Hangzhou
|
||
Sanhua Hongdao")
|
||
Note 6
|
||
6,586,611
|
||
(including
|
||
6,586,611 H
|
||
Shares)
|
||
2.22% 1.67% August 10, 2026
|
||
Note 2
|
||
|
||
|
||
--- page 11 ---
|
||
9
|
||
|
||
|
||
Name
|
||
Number of Shares
|
||
held in the
|
||
Company subject
|
||
to lock-up
|
||
undertakings upon
|
||
Listing
|
||
% of H Shares
|
||
subject to lock-up
|
||
undertakings as to
|
||
total issued H Shares
|
||
upon Listing
|
||
% of Shares subject to
|
||
lock-up undertakings as
|
||
to total issued Shares
|
||
upon Listing
|
||
Last day subject to
|
||
the lock-up
|
||
undertakings
|
||
Xinchang Yujun
|
||
Shanghang Venture
|
||
Capital Partnership
|
||
(Limited Partnership)
|
||
(新昌鈺俊尚行創業
|
||
投資合夥企業(有限
|
||
合夥)) ("Yujun
|
||
Shanghang") Note 6
|
||
2,148,091
|
||
(including
|
||
2,148,091 H
|
||
Shares)
|
||
0.72% 0.55% August 10, 2026
|
||
Note 2
|
||
Jiangsu Province
|
||
Modern Service
|
||
Industry Development
|
||
Venture Capital Fund
|
||
(Limited Partnership)
|
||
(江蘇省現代服務業
|
||
發展創業投資基金(
|
||
有限合夥)) ("Jiangsu
|
||
Modern Service
|
||
Fund") Note 7
|
||
3,078,252
|
||
(including
|
||
3,078,252 H
|
||
Shares)
|
||
1.04% 0.78% August 10, 2026
|
||
Note 2
|
||
Taizhou Transition
|
||
and Upgrading
|
||
Industrial Investment
|
||
Fund (Limited
|
||
Partnership)
|
||
(泰州市轉型升級產
|
||
業投資基金(有限合
|
||
夥)) ("Taizhou
|
||
Transition and
|
||
Upgrading Fund")
|
||
Note 7
|
||
3,078,252
|
||
(including
|
||
3,078,252 H
|
||
Shares)
|
||
1.04% 0.78% August 10, 2026
|
||
Note 2
|
||
Taizhou China
|
||
Pharmaceutical City
|
||
Class I New Drug
|
||
R&D Investment Fund
|
||
Partnership Enterprise
|
||
(Limited Partnership)
|
||
(泰州中國醫藥城一
|
||
類新藥研發投資基金
|
||
合夥企業(有限合夥))
|
||
6,156,342
|
||
(including
|
||
3,078,171 H
|
||
Shars)
|
||
1.04% 1.56% August 10, 2026
|
||
Note 2
|
||
Anji Aiweidi
|
||
Enterprise
|
||
Management
|
||
Partnership (Limited
|
||
Partnership)
|
||
(安吉愛威笛企業管
|
||
4,066,813
|
||
(including 0 H
|
||
Shares)
|
||
0% 1.03% August 10, 2026
|
||
Note 2
|
||
|
||
|
||
--- page 12 ---
|
||
10
|
||
|
||
|
||
Name
|
||
Number of Shares
|
||
held in the
|
||
Company subject
|
||
to lock-up
|
||
undertakings upon
|
||
Listing
|
||
% of H Shares
|
||
subject to lock-up
|
||
undertakings as to
|
||
total issued H Shares
|
||
upon Listing
|
||
% of Shares subject to
|
||
lock-up undertakings as
|
||
to total issued Shares
|
||
upon Listing
|
||
Last day subject to
|
||
the lock-up
|
||
undertakings
|
||
理合夥企業(有限合
|
||
夥)) ("Anji Aiweidi")
|
||
Note 8
|
||
Shangshan Ruoshui
|
||
(Beijing) Fund
|
||
Management Co., Ltd.
|
||
(上善若水(北京)基金
|
||
管理有限公司)
|
||
("Shangshan
|
||
Ruoshui") Note 8
|
||
2,052,114
|
||
(including
|
||
2,052,114 H
|
||
Shares)
|
||
0.69% 0.52% August 10, 2026
|
||
Note 2
|
||
Shenzhen Songhe
|
||
Jiyou No. 3 Venture
|
||
Capital Partnership
|
||
(Limited Partnership)
|
||
(深圳市松禾績優三
|
||
號創業投資合夥企業
|
||
(有限合夥))
|
||
4,296,670
|
||
(including
|
||
2,148,335 H
|
||
Shares)
|
||
0.72% 1.09% August 10, 2026
|
||
Note 2
|
||
Shenzhen Co-win
|
||
Yuanshui Investment
|
||
Partnership (Limited
|
||
Partnership)
|
||
(深圳共贏源水投資
|
||
合夥企業(有限合夥))
|
||
4,137,413
|
||
(including
|
||
4,137,413 H
|
||
Shares)
|
||
1.40% 1.05% August 10, 2026
|
||
Note 2
|
||
Yangzhou Yingdan
|
||
Equity Investment
|
||
Partnership (Limited
|
||
Partnership)
|
||
(揚州盈丹股權投資
|
||
合夥企業(有限合夥))
|
||
Note 9
|
||
4,115,615
|
||
(including
|
||
2,057,807 H
|
||
Shares)
|
||
0.69% 1.05% August 10, 2026
|
||
Note 2
|
||
Gongqingcheng
|
||
Chengshu Phase V
|
||
Medical Industry
|
||
Investment Partnership
|
||
(Limited Partnership)
|
||
(共青城承樹五期醫
|
||
療產業投資合夥企業
|
||
(有限合夥))
|
||
3,437,271
|
||
(including
|
||
3,437,271 H
|
||
Shares)
|
||
1.16% 0.87% August 10, 2026
|
||
Note 2
|
||
Hangzhou Fushi
|
||
Investment
|
||
Management
|
||
Partnership (Limited
|
||
Partnership)
|
||
3,345,361
|
||
(including
|
||
1,672,681 H
|
||
Shares)
|
||
0.56% 0.85% August 10, 2026
|
||
Note 2
|
||
|
||
|
||
--- page 13 ---
|
||
11
|
||
|
||
|
||
Name
|
||
Number of Shares
|
||
held in the
|
||
Company subject
|
||
to lock-up
|
||
undertakings upon
|
||
Listing
|
||
% of H Shares
|
||
subject to lock-up
|
||
undertakings as to
|
||
total issued H Shares
|
||
upon Listing
|
||
% of Shares subject to
|
||
lock-up undertakings as
|
||
to total issued Shares
|
||
upon Listing
|
||
Last day subject to
|
||
the lock-up
|
||
undertakings
|
||
(杭州賦實投資管理
|
||
合夥企業(有限合夥))
|
||
Shenzhen Gaotejia
|
||
Ruibao Investment
|
||
Partnership (Limited
|
||
Partnership)
|
||
(深圳市高特佳睿寶
|
||
投資合夥企業(有限
|
||
合夥))
|
||
3,300,951
|
||
(including
|
||
3,300,951 H
|
||
Shares)
|
||
1.11% 0.84% August 10, 2026
|
||
Note 2
|
||
Nanjing Yihui
|
||
Entrepreneurship
|
||
Investment Partnership
|
||
Enterprise (Limited
|
||
Partnership)
|
||
(南京益慧創業投資
|
||
合夥企業(有限合夥))
|
||
("Yihui Chuangtou")
|
||
Note 10
|
||
2,377,459
|
||
(including
|
||
2,377,459 H
|
||
Shares)
|
||
0.80% 0.60% August 10, 2026
|
||
Note 2
|
||
Nanjing Yidao Equity
|
||
Investment Partnership
|
||
(Limited Partnership)
|
||
(南京益道股權投資
|
||
合夥企業(有限合夥))
|
||
("Nanjing Yidao") Note
|
||
10
|
||
859,399
|
||
(including
|
||
859,399 H
|
||
Shares)
|
||
0.29% 0.22% August 10, 2026
|
||
Note 2
|
||
Shenzhen Dongqi
|
||
Investment
|
||
Development
|
||
Enterprise (Limited
|
||
Partnership)
|
||
(深圳東淇投資發展
|
||
企業(有限合夥))
|
||
3,028,149
|
||
(including
|
||
3,028,149 H
|
||
Shares)
|
||
1.02% 0.77% August 10, 2026
|
||
Note 2
|
||
Yangzhou Litian New
|
||
Drug Investment
|
||
Partnership Enterprise
|
||
(Limited Partnership)
|
||
(揚州利田新藥投資
|
||
合夥企業(有限合夥))
|
||
Note 11
|
||
2,352,895
|
||
(including
|
||
2,352,895 H
|
||
Shares)
|
||
0.79% 0.60% August 10, 2026
|
||
Note 2
|
||
Guangxi Guangtou
|
||
Guohong Health
|
||
Industry Fund
|
||
Partnership Enterprise
|
||
1,718,635
|
||
(including 0 H
|
||
Shares)
|
||
0% 0.44% August 10, 2026
|
||
Note 2
|
||
|
||
|
||
--- page 14 ---
|
||
12
|
||
|
||
|
||
Name
|
||
Number of Shares
|
||
held in the
|
||
Company subject
|
||
to lock-up
|
||
undertakings upon
|
||
Listing
|
||
% of H Shares
|
||
subject to lock-up
|
||
undertakings as to
|
||
total issued H Shares
|
||
upon Listing
|
||
% of Shares subject to
|
||
lock-up undertakings as
|
||
to total issued Shares
|
||
upon Listing
|
||
Last day subject to
|
||
the lock-up
|
||
undertakings
|
||
(Limited Partnership)
|
||
(廣西廣投國宏健康
|
||
產業基金合夥企業(
|
||
有限合夥))
|
||
Yangzhou Xuantan
|
||
Investment Co., Ltd.
|
||
(揚州玄壇投資有限
|
||
公司) Note 12
|
||
1,626,725
|
||
(including
|
||
650,705 H
|
||
Shares)
|
||
0.22% 0.41% August 10, 2026
|
||
Note 2
|
||
Qingdao Qiandao
|
||
Yingyue Investment
|
||
Management Center
|
||
(Limited Partnership)
|
||
(青島乾道盈悅投資
|
||
管理中心(有限合夥))
|
||
859,399
|
||
(including
|
||
859,399 H
|
||
Shares)
|
||
0.29% 0.22% August 10, 2026
|
||
Note 2
|
||
Shenzhen Zhiyou
|
||
Pengbo Management
|
||
Consulting Partnership
|
||
(Limited Partnership)
|
||
(深圳市志友蓬勃管
|
||
理諮詢合夥企業(有
|
||
限合夥))
|
||
257,836
|
||
(including
|
||
257,836 H
|
||
Shares)
|
||
0.09% 0.07% August 10, 2026
|
||
Note 2
|
||
Subtotal
|
||
169,271,179
|
||
(including
|
||
110,958,752 H
|
||
Shares)
|
||
37.44% 43.02%
|
||
Notes:
|
||
1. Please refer to the section headed “History, Development and Corporate Structure — Pre-IPO
|
||
Investments —Information about Our Pre -IPO Investors” in the Prospectus for details of the Pre -
|
||
IPO Investors.
|
||
2. The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.
|
||
3. Each an investment arm of Shanghai Wenzhou Investment Management Co., Ltd. (上海文周投資管
|
||
理有限公司).
|
||
4. Each an investment arm of Yingke Innovation Asset Management Co., Ltd. ( 盈科創新資產管理有
|
||
限公司).
|
||
5. Each an investment arm of Sealand Innovation Capital Investment Management Co., Ltd. ( 國海創
|
||
新資本投資管理有限公司).
|
||
6. Each ultimately controlled by Mr. Chen Jinyu (陳金玉).
|
||
|
||
|
||
--- page 15 ---
|
||
13
|
||
|
||
|
||
Name
|
||
Number of Shares
|
||
held in the
|
||
Company subject
|
||
to lock-up
|
||
undertakings upon
|
||
Listing
|
||
% of H Shares
|
||
subject to lock-up
|
||
undertakings as to
|
||
total issued H Shares
|
||
upon Listing
|
||
% of Shares subject to
|
||
lock-up undertakings as
|
||
to total issued Shares
|
||
upon Listing
|
||
Last day subject to
|
||
the lock-up
|
||
undertakings
|
||
7. Each an investment arm of Taizhou Yida is Nanjing Yida Equity Investment Management Enterprise
|
||
(Limited Partnership) (南京毅達股權投資管理企業(有限合夥)).
|
||
8. Anji Aiweidi is ultimately controlled by Mr. Lu Yingxu ( 盧迎旭 ); and Shangshan Ruoshui is
|
||
controlled as to 60% by Mr. Lu Yubo (盧玉波), father of Mr. Lu Yingxu, and 40% by Mr. Lu Yingxu.
|
||
9. Yangzhou Yingdan Equity Investment Partnership (Limited Partnership) ( 揚州盈丹股權投資合夥
|
||
企業(有限合夥)) is formerly known as Guangdong Yingdan Equity Investment Partnership (Limited
|
||
Partnership) (廣東盈丹股權投資合夥企業(有限合夥).
|
||
10. Each an investment arm of Nanjing Changchengit Equity Investment Fund Management Enterprise
|
||
(Limited Partnership) (南京常呈益股權投資基金管理企業(有限合夥)).
|
||
11. Yangzhou Litian New Drug Investment Partnership Enterprise (Limited Partnership) ( 揚州利田新
|
||
藥投資合夥企業 ( 有限合夥 )) is formerly known as Zhuzhou Litian New Drug Enterprise
|
||
Management Partnership (Limited Partnership) (株洲市利田新藥企業 管理合夥企業(有限合夥)).
|
||
12. Yangzhou Xuantan Investment Co., Ltd. (揚州玄壇投資有限公司) is formerly known as Guangdong
|
||
Xuantan Investment Co., Ltd. (廣東玄壇投資有限公司).
|
||
|
||
Existing Shareholders (other than the Controlling Shareholders and the Pre-IPO Investors as defined in the
|
||
Prospectus)
|
||
Name
|
||
Number of Shares
|
||
held in the Company
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
% of H Shares
|
||
subject to lock-up
|
||
undertakings as to
|
||
total issued H Shares
|
||
upon Listing
|
||
% of Shares subject
|
||
to lock-up
|
||
undertakings as to
|
||
total issued Shares
|
||
upon Listing
|
||
Last day subject to
|
||
the lock-up
|
||
undertakings
|
||
Shanghai Yijiucheng
|
||
Investment Co., Ltd.
|
||
(上海憶久誠投資有
|
||
限公司)
|
||
26,743,364
|
||
(including
|
||
26,743,364 H
|
||
Shares)
|
||
9.02% 6.80% August 10, 2026
|
||
Note 1
|
||
Subtotal
|
||
26,743,364
|
||
(including
|
||
26,743,364 H
|
||
Shares)
|
||
9.02% 6.80%
|
||
Note:
|
||
1. The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.
|
||
|
||
|
||
--- page 16 ---
|
||
14
|
||
|
||
|
||
|
||
Cornerstone Investor
|
||
Name
|
||
Number of H Shares
|
||
held in the Company
|
||
subject to lock-up
|
||
undertakings upon
|
||
Listing
|
||
% of H Shares
|
||
subject to lock-up
|
||
undertakings as to
|
||
total issued H Shares
|
||
upon Listing
|
||
% of Shares subject
|
||
to lock-up
|
||
undertakings as to
|
||
total issued Shares
|
||
upon Listing
|
||
Last day subject to
|
||
the lock-up
|
||
undertakingsNote 1
|
||
Jiaxing Xinyang and
|
||
HTCI (in connection
|
||
with Huatai Back-to-
|
||
back TRS and Huatai
|
||
Client TRS)
|
||
7,830,600 2.64% 1.99% February 10, 2026
|
||
|
||
Notes:
|
||
1. In accordance with the relevant cornerstone investment agreement, the required lock-up ends on
|
||
February 10, 2026 . The Cornerstone Investor will cease to be prohibited from disposing of or
|
||
transferring H Shares subscribed pursuant to the relevant cornerstone investment agreement after
|
||
the indicated date.
|
||
|
||
|
||
--- page 17 ---
|
||
15
|
||
|
||
|
||
PLACEE CONCENTRATION ANALYSIS
|
||
Placees*
|
||
Number of H Shares
|
||
allotted
|
||
Allotment as % of
|
||
International Offering
|
||
Allotment as % of total
|
||
Offer Shares
|
||
Number of H Shares
|
||
held upon Listing
|
||
% of H Shares held as
|
||
to total issued H Shares
|
||
upon Listing
|
||
% of H Shares held as
|
||
to total issued Shares
|
||
upon Listing
|
||
Top 1 9,800,000 33.28% 29.30% 9,800,000 3.31% 2.49%
|
||
Top 5 27,810,000 94.44% 83.16% 27,810,000 9.38% 7.07%
|
||
Top 10 29,394,600 99.82% 87.90% 29,394,600 9.92% 7.47%
|
||
Top 25 29,419,400 99.91% 87.97% 29,419,400 9.93% 7.48%
|
||
|
||
Note:
|
||
* Ranking of placees is based on the number of H Shares allotted to the placees.
|
||
|
||
|
||
--- page 18 ---
|
||
16
|
||
|
||
|
||
H SHAREHOLDER CONCENTRATION ANALYSIS
|
||
H
|
||
Shareholders*
|
||
Number of H
|
||
Shares allotted
|
||
Allotment as % of
|
||
International
|
||
Offering
|
||
Allotment as % of
|
||
total Offer Shares
|
||
Number of H Shares
|
||
held upon Listing
|
||
% of H Shares
|
||
held as to total
|
||
issued H Shares
|
||
upon Listing
|
||
% of H Shares held
|
||
as to total issued
|
||
Shares upon Listing
|
||
% of Shares held as
|
||
to total issued Shares
|
||
upon Listing
|
||
Top 1 - 0.00% 0.00% 125,217,129 42.25% 31.83% 41.68%
|
||
Top 5 - 0.00% 0.00% 190,758,509 64.37% 48.48% 64.59%
|
||
Top 10 17,630,600 59.87% 52.72% 236,479,483 79.79% 60.11% 78.18%
|
||
Top 25 27,810,000 94.44% 83.16% 287,288,624 96.94% 73.02% 96.58%
|
||
|
||
Note:
|
||
* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.
|
||
|
||
|
||
--- page 19 ---
|
||
17
|
||
|
||
|
||
SHAREHOLDER CONCENTRATION ANALYSIS
|
||
Shareholders*
|
||
Number of H
|
||
Shares allotted
|
||
Allotment as % of
|
||
International
|
||
Offering
|
||
Allotment as % of
|
||
total Offer Shares
|
||
Number of H
|
||
Shares held
|
||
upon Listing
|
||
Number of Shares
|
||
held upon Listing
|
||
% of H Shares held as to
|
||
total issued H Shares
|
||
upon Listing
|
||
% of Shares held as to
|
||
total issued Shares upon
|
||
Listing
|
||
Top 1 - 0.00% 0.00% 125,217,129 163,985,457 42.25% 41.68%
|
||
Top 5 - 0.00% 0.00% 188,180,393 259,295,130 63.50% 65.90%
|
||
Top 10 9,800,000 33.28% 29.30% 234,292,156 315,654,449 79.06% 80.23%
|
||
Top 25 25,984,800 88.24% 77.70% 287,136,105 381,522,205 96.89% 96.97%
|
||
|
||
Note:
|
||
* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholders upon Listing.
|
||
|
||
|
||
--- page 20 ---
|
||
18
|
||
|
||
|
||
BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING
|
||
Subject to the satisfaction of the conditions set out in the Prospectus, a total of 191,879 valid
|
||
applications made by the public will be conditionally allocated on the basis set out below:
|
||
Approximate
|
||
Pool A percentage
|
||
allotted of the
|
||
Number of Number total number of
|
||
H Shares of valid H Shares applied
|
||
applied for applications Basis of allocation/ballot for
|
||
|
||
200 33,581 336 out of 33,581 applicants to receive 200 H Shares 1.00%
|
||
400 6,889 94 out of 6,889 applicants to receive 200 H Shares 0.68%
|
||
600 15,279 247 out of 15,279 applicants to receive 200 H Shares 0.54%
|
||
800 4,125 76 out of 4,125 applicants to receive 200 H Shares 0.46%
|
||
1,000 6,226 126 out of 6,226 applicants to receive 200 H Shares 0.40%
|
||
1,200 4,499 99 out of 4,499 applicants to receive 200 H Shares 0.37%
|
||
1,400 3,519 83 out of 3,519 applicants to receive 200 H Shares 0.34%
|
||
1,600 2,292 57 out of 2,292 applicants to receive 200 H Shares 0.31%
|
||
1,800 1,958 52 out of 1,958 applicants to receive 200 H Shares 0.30%
|
||
2,000 10,789 295 out of 10,789 applicants to receive 200 H Shares 0.27%
|
||
3,000 7,573 248 out of 7,573 applicants to receive 200 H Shares 0.22%
|
||
4,000 4,009 149 out of 4,009 applicants to receive 200 H Shares 0.19%
|
||
5,000 3,323 136 out of 3,323 applicants to receive 200 H Shares 0.16%
|
||
6,000 5,770 255 out of 5,770 applicants to receive 200 H Shares 0.15%
|
||
7,000 2,970 141 out of 2,970 applicants to receive 200 H Shares 0.14%
|
||
8,000 2,167 109 out of 2,167 applicants to receive 200 H Shares 0.13%
|
||
9,000 1,775 94 out of 1,775 applicants to receive 200 H Shares 0.12%
|
||
10,000 13,487 745 out of 13,487 applicants to receive 200 H Shares 0.11%
|
||
20,000 9,337 698 out of 9,337 applicants to receive 200 H Shares 0.07%
|
||
30,000 5,624 502 out of 5,624 applicants to receive 200 H Shares 0.06%
|
||
40,000 4,600 465 out of 4,600 applicants to receive 200 H Shares 0.05%
|
||
50,000 3,276 366 out of 3,276 applicants to receive 200 H Shares 0.04%
|
||
60,000 2,856 345 out of 2,856 applicants to receive 200 H Shares 0.04%
|
||
70,000 2,523 326 out of 2,523 applicants to receive 200 H Shares 0.04%
|
||
80,000 1,781 244 out of 1,781 applicants to receive 200 H Shares 0.03%
|
||
90,000 1,507 218 out of 1,507 applicants to receive 200 H Shares 0.03%
|
||
100,000 8,561 1,292 out of 8,561 applicants to receive 200 H Shares 0.03%
|
||
200,000 5,385 1,100 out of 5,385 applicants to receive 200 H Shares 0.02%
|
||
300,000 4,480 1,092 out of 4,480 applicants to receive 200 H Shares 0.02%
|
||
|
||
Total 180,161 Total number of Pool A successful applicants: 9,990
|
||
|
||
|
||
|
||
Pool B Approximate
|
||
percentage
|
||
allotted of the
|
||
Number Number total number of
|
||
of H Shares of valid H Shares applied
|
||
applied for applications Basis of allocation/ballot for
|
||
|
||
400,000 4,853 2,912 out of 4,853 applicants to receive 200 H Shares 0.03%
|
||
500,000 1,513 1,051 out of 1,513 applicants to receive 200 H Shares 0.03%
|
||
600,000 1,030 806 out of 1,030 applicants to receive 200 H Shares 0.03%
|
||
|
||
|
||
--- page 21 ---
|
||
19
|
||
|
||
|
||
700,000 799 692 out of 799 applicants to receive 200 H Shares 0.02%
|
||
800,000 476 450 out of 476 applicants to receive 200 H Shares 0.02%
|
||
900,000 338
|
||
200 H Shares plus 7 out of 338 applicants to receive an additional 200
|
||
H Shares 0.02%
|
||
|
||
1,000,000
|
||
|
||
567
|
||
200 H Shares plus 53 out of 567 applicants to receive an additional
|
||
200 H Shares 0.02%
|
||
|
||
1,200,000
|
||
|
||
365
|
||
200 H Shares plus 85 out of 365 applicants to receive an additional
|
||
200 H Shares 0.02%
|
||
|
||
1,400,000
|
||
|
||
316
|
||
200 H Shares plus 115 out of 316 applicants to receive an additional
|
||
200 H Shares 0.02%
|
||
|
||
1,672,200
|
||
|
||
1,461
|
||
200 H Shares plus 772 out of 1,461 applicants to receive an additional
|
||
200 H Shares 0.02%
|
||
|
||
Total 11,718 Total number of Pool B successful applicants: 8,958
|
||
|
||
|
||
As of the date of this announcement, the relevant subscription monies previously deposited in the
|
||
designated nominee accounts have been remitted back to the accounts of all HKSCC participants.
|
||
Investors should contact their relevant brokers for any inquiries.
|
||
|
||
|
||
--- page 22 ---
|
||
20
|
||
|
||
|
||
COMPLIANCE WITH LISTING RULES AND GUIDANCE
|
||
The Directors confirm that the Company has complied with the Listing Rules and guidance materials in
|
||
relation to the placing, allotment and listing of the Company’s H Shares.
|
||
The Directors confirm that, to the best of their knowledge, the consideration paid by the placees or the
|
||
public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by
|
||
them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC
|
||
transaction levy and Stock Exchange trading fee payable.
|
||
OTHERS / ADDITIONAL INFORMATION
|
||
Offer Size Adjustment Option and reallocation
|
||
The Offer Size Adjustment Option has not been exercised. As the International Offering has not been
|
||
fully subscribed and the Hong Kong Public Offering has been oversubscribed, the reallocation as
|
||
described in the section headed “Structure of the Global Offering – The Hong Kong Public Offering –
|
||
Reallocation and clawback” of the Prospectus has been applied. As a result of the above, the final number
|
||
of Offer Shares under the Hong Kong Public Offering is adjusted to 3,996,000 Shares, representing
|
||
approximately 11.95% of the total number of Offer Shares available under the Global Offering, and the
|
||
final number of Offer Shares under the International Offering is adjusted to 29,446,600 Shares,
|
||
representing approximately 88.05% of the total number of Offer Shares under the Global Offering.
|
||
DISCLAIMERS
|
||
|
||
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong
|
||
Kong Securities Clearing Company Limited take no responsibility for the contents of this
|
||
announcement, make no representation as to its accuracy or completeness and expressly disclaim
|
||
any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any
|
||
part of the contents of this announcement.
|
||
This announcement is not for release, publication, distribution, directly or indirectly, in or into the
|
||
United States (including its territories and possessions, any state of the United States and the District
|
||
of Columbia). This announcement does not const itute or form a part of any offer or solicitation to
|
||
purchase or subscribe for the Offer Shares in the United States or in any other jurisdictions. The Offer
|
||
Shares have not been, and will not be, registered under the United States Securities Act of 1933 a s
|
||
amended from time to time (the “ U.S. Securities Act ”) or securities law of any state or other
|
||
jurisdiction of the United States. The Offer Shares may not be offered, sold, pledged or otherwise
|
||
transferred within the United States, except pursuant to an exemption from the registration
|
||
requirements of the U.S. Securities Act and U.S. Investment Company Act of 1940, as amended (“U.S.
|
||
Investment Company Act”), and in compliance with any applicable state securities laws. There will
|
||
be no public offer of the Offer Shares in the United States.
|
||
The Offer Shares are being offered and sold outside the United States to investors that are not U.S.
|
||
persons nor persons acquiring for the account or benefit of U.S. persons in reliance on Regulation S
|
||
under the U.S. Securities Act.
|
||
This announcement is for information purposes only and does not constitute an invitation or offer to
|
||
acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential
|
||
investors should read the Prospectus dated July 31, 2025 issued by Ab&B Bio-Tech CO., LTD. JS (江
|
||
蘇中慧元通生物科技股份有限公司) for detailed information about the Global Offering described
|
||
|
||
|
||
--- page 23 ---
|
||
21
|
||
|
||
|
||
below before deciding whether or not to invest in the H Shares thereby being offered.
|
||
*Potential investors of the Offer Shares should note that the Joint Sponsors and the Overall
|
||
Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to
|
||
terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect
|
||
upon the occurrence of any of the events set out in the section headed “Underwriting –
|
||
Underwriting Arrangements and Expenses – Hong Kong Public Offering – Hong Kong Underwriting
|
||
Agreement – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong
|
||
time) on the Listing Date (which is currently expected to be on August 11 , 2025).
|
||
|
||
|
||
--- page 24 ---
|
||
22
|
||
|
||
PUBLIC FLOAT
|
||
Immediately following the completion of the Global Offering, an aggregate of 132,488,550 H Shares or
|
||
approximately 33.67% of the total issued share capital of the Company will be held in the public hands.
|
||
Therefore, the number of H Shares in the public hands represents no less than 25% of the total issued share
|
||
capital of the Company, satisfying the minimum percentage requirement in compliance with Rule 8.08(1) of
|
||
the Listing Rules.
|
||
The Directors confirm that, immediately following the completion of the Global Offering, (i) no placee will,
|
||
individually, be placed more than 10% of the enlarged issued share capital of the Company immediately
|
||
after the Global Offering; (ii) there will not be any new substantial Shareholder immediately after the
|
||
Global Offering; (iii) the three largest public shareholders of the Company do not hold more than 50%
|
||
of the H shares in public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of
|
||
the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of the Listing in compliance
|
||
with Rule 8.08(2) of the Listing Rules.
|
||
COMMENCEMENT OF DEALINGS
|
||
The H Share certificates will only become valid evidence of title at 8:00 a.m. on Monday, August 11,
|
||
2025 (Hong Kong time), provided that the Global Offering has become unconditional and the right of
|
||
termination described in the section headed “Underwriting – Underwriting Arrangements and Expenses
|
||
– Hong Kong Public Offering – Grounds for Termination” in the Prospectus has not been exercised.
|
||
Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt
|
||
of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely
|
||
at their own risk.
|
||
Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Monday,
|
||
August 11, 2025 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange will
|
||
commence at 9:00 a.m. on Monday, August 11, 2025 (Hong Kong time). The H Shares will be traded in
|
||
board lots of 200 H Shares each, and the stock code of the H Shares will be 2627.
|
||
By order of the Board
|
||
Ab&B Bio-Tech CO., LTD. JS
|
||
Mr. AN Youcai
|
||
Executive Director, chairman of the Board and general
|
||
manager
|
||
Hong Kong, August 8, 2025
|
||
As at the date of this announcement, the Board comprises: (i) Mr. AN Youcai, Ms. LI Runxiang and Mr. HE
|
||
Yiming as executive Directors; (ii) Mr. CHENG Qianwen, Mr. YU Jianlin and Mr. DU Mu as non-executive
|
||
Directors; and (iii) Mr. LI Xiangming, Ms. LI Xiaoqing and Mr. CHEN Chengbei as independent non -
|
||
executive Directors.
|